Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma

Hyun Soo Kim, Gun Yoon, Sung Im Do, Sung Joo Kim, Youn Wha Kim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A better understanding of tumor biology is important in the identification of molecules that are down-regulated in malignancy and in determining their role in tumor suppression. The aim of this study was to analyze osteoprotegerin (OPG) expression in colorectal carcinoma (CRC) and to investigate the underlying mechanism for changes in the expression of OPG. OPG expression was assessed in CRC tissue samples and cell lines. The methylation status of the OPG promoter region was determined, and the effects of demethylation on OPG expression were analyzed. The effects of recombinant OPG (rOPG) administration on cellular functions were also investigated. Clinical and prognostic implications of OPG protein expression in CRC patients were analyzed. The CRC tissues and cells showed significantly lower OPG expression. Pyrosequencing of OPG-silenced CRC cells revealed that the OPG gene promoter was highly methylated. Treatment with demethylating agent significantly elevated OPG mRNA and protein expression. rOPG significantly decreased cell viability and MMP-2 and VEGF-A production in CRC cells. Reduced OPG immunoreactivity was associated with aggressive oncogenic behavior in CRC. Also, OPG expression was found to be an independent predictor of recurrent hepatic metastasis and independent prognostic factor for worse survival rates. We demonstrated that OPG silencing in CRC occurs through epigenetic repression, and is involved in the development and progression of CRC. Our data suggest that OPG is a novel prognostic biomarker and a new therapeutic target for the treatment of patients with CRC.

Original languageEnglish
Pages (from-to)15187-15199
Number of pages13
JournalOncotarget
Volume7
Issue number12
DOIs
Publication statusPublished - 2016 Mar 22

Fingerprint

Osteoprotegerin
Colorectal Neoplasms
Down-Regulation
Biomarkers
Epigenetic Repression
Neoplasms
Matrix Metalloproteinases

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kim, Hyun Soo ; Yoon, Gun ; Do, Sung Im ; Kim, Sung Joo ; Kim, Youn Wha. / Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma. In: Oncotarget. 2016 ; Vol. 7, No. 12. pp. 15187-15199.
@article{6b7f333190d74a5aa256e62421496568,
title = "Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma",
abstract = "A better understanding of tumor biology is important in the identification of molecules that are down-regulated in malignancy and in determining their role in tumor suppression. The aim of this study was to analyze osteoprotegerin (OPG) expression in colorectal carcinoma (CRC) and to investigate the underlying mechanism for changes in the expression of OPG. OPG expression was assessed in CRC tissue samples and cell lines. The methylation status of the OPG promoter region was determined, and the effects of demethylation on OPG expression were analyzed. The effects of recombinant OPG (rOPG) administration on cellular functions were also investigated. Clinical and prognostic implications of OPG protein expression in CRC patients were analyzed. The CRC tissues and cells showed significantly lower OPG expression. Pyrosequencing of OPG-silenced CRC cells revealed that the OPG gene promoter was highly methylated. Treatment with demethylating agent significantly elevated OPG mRNA and protein expression. rOPG significantly decreased cell viability and MMP-2 and VEGF-A production in CRC cells. Reduced OPG immunoreactivity was associated with aggressive oncogenic behavior in CRC. Also, OPG expression was found to be an independent predictor of recurrent hepatic metastasis and independent prognostic factor for worse survival rates. We demonstrated that OPG silencing in CRC occurs through epigenetic repression, and is involved in the development and progression of CRC. Our data suggest that OPG is a novel prognostic biomarker and a new therapeutic target for the treatment of patients with CRC.",
author = "Kim, {Hyun Soo} and Gun Yoon and Do, {Sung Im} and Kim, {Sung Joo} and Kim, {Youn Wha}",
year = "2016",
month = "3",
day = "22",
doi = "10.18632/oncotarget.7885",
language = "English",
volume = "7",
pages = "15187--15199",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "12",

}

Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma. / Kim, Hyun Soo; Yoon, Gun; Do, Sung Im; Kim, Sung Joo; Kim, Youn Wha.

In: Oncotarget, Vol. 7, No. 12, 22.03.2016, p. 15187-15199.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma

AU - Kim, Hyun Soo

AU - Yoon, Gun

AU - Do, Sung Im

AU - Kim, Sung Joo

AU - Kim, Youn Wha

PY - 2016/3/22

Y1 - 2016/3/22

N2 - A better understanding of tumor biology is important in the identification of molecules that are down-regulated in malignancy and in determining their role in tumor suppression. The aim of this study was to analyze osteoprotegerin (OPG) expression in colorectal carcinoma (CRC) and to investigate the underlying mechanism for changes in the expression of OPG. OPG expression was assessed in CRC tissue samples and cell lines. The methylation status of the OPG promoter region was determined, and the effects of demethylation on OPG expression were analyzed. The effects of recombinant OPG (rOPG) administration on cellular functions were also investigated. Clinical and prognostic implications of OPG protein expression in CRC patients were analyzed. The CRC tissues and cells showed significantly lower OPG expression. Pyrosequencing of OPG-silenced CRC cells revealed that the OPG gene promoter was highly methylated. Treatment with demethylating agent significantly elevated OPG mRNA and protein expression. rOPG significantly decreased cell viability and MMP-2 and VEGF-A production in CRC cells. Reduced OPG immunoreactivity was associated with aggressive oncogenic behavior in CRC. Also, OPG expression was found to be an independent predictor of recurrent hepatic metastasis and independent prognostic factor for worse survival rates. We demonstrated that OPG silencing in CRC occurs through epigenetic repression, and is involved in the development and progression of CRC. Our data suggest that OPG is a novel prognostic biomarker and a new therapeutic target for the treatment of patients with CRC.

AB - A better understanding of tumor biology is important in the identification of molecules that are down-regulated in malignancy and in determining their role in tumor suppression. The aim of this study was to analyze osteoprotegerin (OPG) expression in colorectal carcinoma (CRC) and to investigate the underlying mechanism for changes in the expression of OPG. OPG expression was assessed in CRC tissue samples and cell lines. The methylation status of the OPG promoter region was determined, and the effects of demethylation on OPG expression were analyzed. The effects of recombinant OPG (rOPG) administration on cellular functions were also investigated. Clinical and prognostic implications of OPG protein expression in CRC patients were analyzed. The CRC tissues and cells showed significantly lower OPG expression. Pyrosequencing of OPG-silenced CRC cells revealed that the OPG gene promoter was highly methylated. Treatment with demethylating agent significantly elevated OPG mRNA and protein expression. rOPG significantly decreased cell viability and MMP-2 and VEGF-A production in CRC cells. Reduced OPG immunoreactivity was associated with aggressive oncogenic behavior in CRC. Also, OPG expression was found to be an independent predictor of recurrent hepatic metastasis and independent prognostic factor for worse survival rates. We demonstrated that OPG silencing in CRC occurs through epigenetic repression, and is involved in the development and progression of CRC. Our data suggest that OPG is a novel prognostic biomarker and a new therapeutic target for the treatment of patients with CRC.

UR - http://www.scopus.com/inward/record.url?scp=84962815384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962815384&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7885

DO - 10.18632/oncotarget.7885

M3 - Article

C2 - 26942563

AN - SCOPUS:84962815384

VL - 7

SP - 15187

EP - 15199

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 12

ER -